ENvue Medical, Inc. insider Christian Michael Glibert filed a Form 4 showing no change in his share count, while his beneficial ownership percentage dropped below 10 percent. He continues to hold 240,000 shares of Common Stock directly. The footnote explains that his reduced percentage resulted from dilution after ENvue issued additional shares in connection with a merger described in its Form 10-K, meaning no shares were acquired or disposed of by him.
Christian Michael Glibert reports an updated beneficial ownership position in ENvue Medical, Inc. common stock. He continues to hold 240,000 shares, which now represent 6.5% of the company’s outstanding common stock.
The change in percentage results from ENvue Medical’s total shares outstanding increasing from 1,088,192 to 3,700,908, as disclosed in the company’s Annual Report on Form 10‑K filed on April 15, 2026. Glibert has not acquired or disposed of any shares since his initial Schedule 13D filed on February 11, 2026 and states he holds the position for investment purposes, while reserving the option to buy or sell shares in the future depending on market conditions.
ENvue Medical, Inc., formerly NanoVibronix, filed its annual report describing a major 2025 merger and a shift to a dual-business medical device model. The company acquired ENvue Medical Holdings, adding an enteral feeding navigation platform alongside its legacy ultrasound-based PainShield and UroShield therapies.
Following the merger, ENvue operates through Israeli subsidiary Nano OpCo for pain and biofilm-related devices, and ENvue Medical Holdings LLC for electromagnetic navigation-guided enteral feeding systems and related disposables. The company executed 1‑for‑11 and 1‑for‑10 reverse stock splits in 2025 and reported approximately $7.3 million aggregate market value of voting stock held by non‑affiliates and 3,700,908 common shares outstanding.
ENvue Medical, Inc. reports an amended Schedule 13G showing 0.0% ownership by Bank of America Corporation. The filing states 14 shares beneficially owned with 14 shares of shared voting and dispositive power. The beneficial ownership calculation cites December 5, 2025 outstanding share totals of 1,088,192 from a Form 424B3 prospectus.
ENvue Medical, Inc. reported that Nicole M. Fernandez-McGovern, the company’s Interim CFO, filed an initial statement of beneficial ownership on Form 3. This filing establishes her official insider status and discloses her equity position in the company as required for officers under SEC rules.
Envue Medical, Inc. insider Christian Michael Glibert, a more than 10% owner, reports beneficial ownership of 240,000 shares of common stock held directly as of January 14, 2026. The company states there were 1,088,192 shares of common stock outstanding as of February 2026; this is a baseline figure, not the amount reported as owned.
ENvue Medical 10% owner Christian Michael Glibert bought 240,000 common shares in the open market. The purchase on January 14, 2026 was at a weighted average price of $2.67 per share, with individual trades ranging from $2.47 to $2.90.
Following this transaction, Glibert directly owns 240,000 shares of ENvue Medical common stock. A footnote states that the ownership percentage is calculated against 1,088,192 shares of common stock outstanding as of the issuer’s most recent February 2026 filings, indicating this is a meaningful stake.
ENvue Medical, Inc. shareholder Christian Michael Glibert filed a Schedule 13D disclosing beneficial ownership of 240,000 shares of common stock, representing about 22.05% of the company based on 1,088,192 shares outstanding as of February 2026. On January 14, 2026, he purchased 240,000 shares in an open market transaction at an average price of $2.67 per share, using personal funds totaling approximately $640,737.85. He states the shares were acquired for investment purposes and that he may buy more or sell some in the future, but reports no current plans for corporate actions and no contracts or arrangements with others regarding the issuer’s securities.
Bank of America Corporation filed a Schedule 13G reporting beneficial ownership of 234,235 shares of ENvue Medical common stock, representing 21.5% of the outstanding class.
The filing shows Bank of America, through BofA Securities, Inc. and Bank of America N.A., has shared voting and dispositive power over these shares and certifies the position is held in the ordinary course of business without the purpose of influencing control. The disclosure notes that the ownership percentage is based on 1,088,192 outstanding shares from a recent ENvue prospectus, which also describes a potential resale of up to 7,962,279 additional shares that could significantly increase outstanding shares and dilute existing holders.